05:15 PM EDT, 10/08/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) outlined five research collaboration projects to study molecular residual disease testing in breast cancer using the company's Precise MRD test.

The research collaborations involve the University of Texas MD Anderson Cancer Center, the University of Rochester Medical Center, the National Cancer Center Hospital East in Japan, a partnership with Aptitude Health and a multicenter study, Myriad said Tuesday in a statement.

"Relative to many other cancer types that typically have high levels of ctDNA in the blood, breast cancer often has very low levels of ctDNA, which makes MRD testing a challenge," Myriad Chief Scientific Officer Dale Muzzey said in the statement.

"Myriad's Precise MRD test is well suited to overcome this challenge because it tracks up to 1,000 tumor-specific variants identified via whole-genome sequencing," Muzzey said.